Previous 10 | Next 10 |
2024-04-30 13:42:09 ET More on Geron Considering The Merits Of A Gamble On Geron Corporation Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA TD Cowen starts ...
2024-04-29 15:07:00 ET More on Geron Considering The Merits Of A Gamble On Geron Corporation Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA Geron announces ...
2024-04-28 04:39:02 ET Summary Today, we look at three small-cap biotech/biopharma stocks. All three have attractive risk/reward profiles and potential catalysts on the horizon. An investment synopsis on all three firms is presented in the paragraphs below. Today, we...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the market opens on Thursday, May 2, 2024 via press release, which will be available on the Companyȁ...
2024-04-11 15:56:04 ET Summary The FDA advisory committee voted 12-2 in favor of imetelstat's clinical profile in lower-risk myelodysplastic syndromes. The PDUFA target date for GERN's imetelstat NDA is June 16, 2024. An interim analysis in GERN's IMpactMF study in myelofibros...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences: 23 rd Annual Needham Virtual Health...
2024-03-19 09:21:13 ET More on Geron Geron: Advisory Nod Boosts Approval Odds, But Market Position Remains Hazy Geron Post 2023 Earnings - Gearing Up For Critical Imetelstat AdCom, PDUFA Geron Corporation (GERN) Q4 2023 Earnings Call Transcript Geron surges a...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock. Th...
2024-03-18 05:21:00 ET 3 Hot Tips for Choosing the Right Penny Stocks to Buy Navigating the realm of penny stocks can unlock pathways to significant financial growth, presenting a landscape ripe with opportunities for those astute enough to capitalize on them. Central to achieving succe...
2024-03-17 10:45:34 ET 3 Tips for Capitalizing on Market Cycles to Make Money With Penny Stocks Capitalizing on market cycles offers a strategic advantage in trading penny stocks, enabling investors to navigate through volatility and harness opportunities for significant returns. Unders...
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...